首页> 外文OA文献 >Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

【2h】

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

机译：达沙替尼或尼罗替尼治疗慢性粒细胞白血病患者，对两种先前给予的酪氨酸激酶抑制剂无效 - 单中心体验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Beatriz Felicio Ribeiro; Eliana C.M. Miranda; Dulcinéia Martins de Albuquerque; Márcia T. Delamain; Gislaine Oliveira-Duarte; Maria Helena Almeida; Bruna Vergílio; Rosana Antunes da Silveira; Vagner Oliveira-Duarte; Irene Lorand-Metze; Carmino A. De Souza; Katia B.B. Pagnano;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience [J] . Beatriz Felicio Ribeiro, Bruna Vergílio, Carmino A. De Souza, Clinics . 2015,第8期

机译：达沙替尼或尼罗替尼治疗慢性髓性白血病患者，这些患者对两种先前使用的酪氨酸激酶抑制剂没有反应-单中心经验
2. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature [J] . Seniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, Hematology . 2018,第4期

机译：先前两次TKI后用第二代酪氨酸激酶抑制剂（达沙替尼或尼洛替尼）进行三线治疗的慢性粒细胞白血病患者：单中心经验的真实数据以及文献综述
3. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature [J] . Ongoren Seniz, Eskazan Ahmet Emre, Suzan Veysel, Hematology. . 2018,第4期

机译：在慢性骨髓白血病患者中使用第二代酪氨酸激酶抑制剂（Dasatinib或Nilotinib）的第三线治疗在两次先前的TKIS之后：单一中心经验的现实数据以及文献的审查
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Design synthesis and biological evaluation of bioisosteric analogues of dasatinib as Src, Abl and Abl T3151 protein tyrosine kinase inhibitors [D] . Patel, Jay P. 2013

机译：dasatinib作为Src，Abl和Abl T3151蛋白酪氨酸激酶抑制剂的生物立体异构体的设计合成和生物学评估
6. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience [O] . Beatriz Felicio Ribeiro, Eliana C M Miranda, Dulcinéia Martins de Albuquerque, 2015

机译：达沙替尼或尼洛替尼治疗慢性髓性白血病患者这些患者对两种先前使用的酪氨酸激酶抑制剂均无反应-单中心经验
7. PCN160 Cost-Effectiveness Of First-Line Tyrosine Kinase Inhibitors (Tkis) In Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients In Korea: Comparison Of Dasatinib (100mg), Nilotinib (600mg) And Imatinib (400mg) [O] . Shin M, Shin S, Lee JY, 2015

机译：一线酪氨酸激酶抑制剂（Tkis）在韩国新诊断的慢性粒细胞白血病（Cml）患者中的PCN160成本-效果：达沙替尼（100mg），尼洛替尼（600mg）和伊马替尼（400mg）的比较

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

著录项

相似文献

相关主题

期刊订阅